|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Asthma/COPD - ICS/LABA Combinations Continue to Dominate
Datamonitor, Aug 2006, Pages: 168
The respiratory market will continue to experience strong growth for the next 6 years, driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark studies. Despite patent expiries of three leading products, from 2010, the market will avoid a collapse like the one seen for oral antihistamines.
Scope of this title:
- Indication based forecasts for asthma/COPD products and significant pipeline drugs
- Assessment of country-specific drivers and resistors likely to impact the market
- Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates
- Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance
Highlights of this title:
- Global asthma/COPD sales should grow to over $30 billion by 2012 and remain flat thereafter, with inhaled corticosteroid/long-acting bronchodilator combinations set to remain the leading class by value throughout. Anticholinergics will experience the strongest growth, particularly in COPD, to become the second-best selling class.
- GSKs Super Advair should become the top-selling brand in the seven major markets in 2015 if the company manages to switch Seretide/Advair prescriptions successfully before Seretides US patent expires.
- The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2 agonists (SABAs), more than doubling its size. The main beneficiary will be Sepracors Xopenex MDI.
Reasons to order your copy:
- Identify key opportunities and threats that will impact the use and uptake of new and existing products
- Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds
- Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
Customers who bought this item also bought
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Asthma And COPD - Get Smart
Forecast Insight: Asthma/COPD - Little Long-term Future for Long-acting Single-agent Inhalers?
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Asthma and COPD Market Forecast
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Commercial Insight: Asthma and COPD - Control is the Goal
Asthma and COPD Drug Discoveries: What the Future Holds
IMS Therapy Report: Asthma & COPD
|
|
|
|
